Fig. 3.

Pharmacological blockade of Per1 nuclear entry results in decreased 3β-HSD expression in vitro. A and B: NCI-H295R cells were treated with the casein kinase (CK)1-δ/ε inhibitor (CKinh) PF-670462 at either 0.1, 1, 10, or 100 μM for 24, 48, or 72 h. Quantitative PCR was used to evaluate changes in 3β-HSD (A) and CYPB11 (B) gene expression in PF-670462-treated versus water-treated cells. Values are presented as means ± SE; n = 3. *P < 0.05; **P < 0.01. C: nuclear extracts were collected from NCI-H295R cells treated with 0.1 μM of the CK-1δ/ε inhibitor PF-670462 or water for 24 h. Western blot analysis was performed using anti-Per1 or anti-β-actin antibodies as a loading control. Data are representative of three independent experiments. D: densitometry analysis was used to quantitate the level of Per1 in C. Values are presented as means ± SE; n = 3. *P < 0.05.